US/UK/Canada

Share

Contacts

  • Elos Medtech AB (publ)
    Torsgatan 5B, 411 04 Göteborg
    +46 10 - 171 20 00
    http://www.elosmedtech.com

    • Quotes

    “We will continue to collaborate with our present customers, but also increase our collaboration with technical partners”
    Soren Olesen, Dental Business Director, Elos Medtech
    “Keeping a close dialogue with our partners and maintaining a high level of competence has led to a product portfolio with the right focus – simple and innovative dental products for an open digital workflow.”
    Soren Olesen, Dental Business Director, Elos Medtech
    Elos Medtech is excited to highlight orthopaedics as one of the primary areas of focus and to execute on our market specific strategies. This is a natural step toward achieving our growth targets and capitalizing on our 2015 acquisition of Onyx Medical
    Jan Wahlström, CEO and President.
    Pick a time period -
    Tags ( Active)

    Elos clarifies focus – changes name to Elos Medtech

    On 27 April 2015, the Annual General Meeting of Elos AB (publ) resolved to change the company’s name/registered name to Elos Medtech AB. Since 1989, the company has been listed on Nasdaq Nordic Stockholm Exchange, the Small Cap list, with a classification in the Health Care sector since February 2008. In recent years, Elos Medtech’s operations have been streamlined based on a well-defined strategy to develop and strengthen the Group’s market position in selected medical technology segments and to create a global structure. To highlight the focus of the operation and create a more

    Elos AB (publ) – Annual General Meeting 2015

    The Annual General Meeting (AGM) resolved -  Dividend for fiscal year 2014 of SEK 3.00 per share-  Company name change to Elos Medtech AB-  Yvonne Mårtensson as new member of the Board At the AGM of Elos AB on April 27 2015, the Board’s proposal of a dividend for fiscal year 2014 ofSEK 2.00 per share and SEK 1.00 per share as a special dividend was approved. President Johannes Lind-Widestam provided information about the business trend during 2014 and presented the interim report for the first quarter of 2015. The Annual General Meeting resolved to adopt a new Articles of

    Elos Interim report, 1 January–31 March 2015

    · 23 April marked the conclusion of the acquisition of the North American company, Onyx Medical LLC, based in Memphis, TN, US. The company is a leading supplier to the Trauma & Extremities segment in the Orthopaedics area. · Net sales increased and totalled SEK 105.5 M (88.5), a rise of 11.7%*. Order bookings amounted to SEK 96.1 M (115.4), down 21.6%*. · Operating profit totalled SEK 5.7 M (6.3). Earnings for the quarter were adversely affected by non-recurring expenses of SEK 4.5 M (0). Adjusted for these items, operating profit amounted to SEK 10.2 M, with the year-on-year

    Elos acquires US based Onyx Medical, a leading supplier to the Orthopaedic Trauma and Extremities markets

    Elos has entered into an agreement to acquire US based Onyx Medical Corporation, a leading supplier of Trauma and Extremities products to the top Orthopaedics companies.  Swedish based Elos is one of Europe’s leading solution partners in the development and manufacturing of high precision products and components used in medical technology, such as dental and orthopaedic implants and instruments. Operations are conducted at facilities in Sweden, Denmark and China. The acquisition of Onyx is part of Elos’s well-defined strategy to focus entirely on the Medical Device Industry while

    Official notification of Annual General Meeting of Elos AB (publ)

    The shareholders of Elos AB (publ), 556021-9650 are hereby invited to the Annual General Meeting to be held on Monday 27 April 2015, at 5.00 p.m. (CET) at Stadt Hotel, Gamla Stadens Torg 1, Lidköping, Sweden.Registration Shareholders who wish to participate in the Annual General Meeting must Firstly, be recorded in the share register maintained by Euroclear Sweden AB on Tuesday April 21, 2015, and Secondly, give notice to the company of their intention to attend no later than 12:00 noon (CET) on Tuesday April 21, 2015, by writing to the company at Nya Stadens Torg 10,SE-531 31

    Yvonne Mårtensson proposed as Board member of Elos AB

    The Nomination Committee of Elos AB will propose that the Annual General Meeting re-elect Board members Stig-Arne Blom (Chairman of the Board), Agneta Bengtsson Runmarker, Jeppe Magnusson, Mats Nilsson and Thomas Öster. In addition, the Nomination Committee will propose that Yvonne Mårtensson be elected as a new Board member. The current members Göran Brorsson and Erik Löwenadler have announced that they will be declining re-election. Yvonne Mårtensson has an M.Sc. degree from Linköping Technical University. She has held a large number of positions in international marketing and sales of

    Elos Year-end report, 1 January – 31 December 2014

    · Net sales for continuing operations increased to SEK 380.9 M (368.1), corresponding to an increase of 0.7%.* Order bookings for continuing operations amounted to SEK 418.1 M (356.5), up 12.9%.* · Operating profit for continuing operations amounted to SEK 33.1 M (27.2). The higher earnings were primarily due to continued efficiency improvement. Earnings for the year were negatively impacted by non-recurring costs of SEK 3.4 M (0). · Profit after net financial items for continuing operations amounted to SEK 31.8 M (21.5). Net financial items were positively impacted by exchange-rate

    Elos Medtech to enlarge plant in Skara

    Elos Medtech Microplast, a company in the Elos Group, will be expanding its plant in Skara by 1,500 square metres due to increased demand for injection-moulded plastic components from customers in the medical-technology sector. During 2014, Elos Medtech Microplast invested in sterile rooms for assembly, packaging and production in a sterile room environment. Production in Skara is largely automated and the operation is ISO 13485 certified. The company’s MD, Mathias Andersson, says: “The increase in our market activities and a distinct business strategy combined with being part of Elos

    Elos Nomination Committee appointed ahead of Annual General Meeting 2015

    In accordance with resolutions passed at the Annual General Meeting in 2014, the Elos Nomination Committee shall comprise no fewer than four and no more than six members, of whom one is to be the Chairman of the Board. The members are to be appointed by those shareholders who, at the end of the month of September, are the largest shareholders in terms of voting rights in the company, as well as by the party who addition to the aforementioned is the largest shareholder. If a shareholder should waive his/her entitlement to appoint a member, such entitlement switches to the next largest

    Elos appoints Johannes Lind-Widestam as new President and CEO as of 1 February 2015

    President and CEO Göran Brorsson has decided to step down as of 31 January 2015Following more than 14 years as President and CEO of Elos (former Westergyllen), President and CEO Göran Brorsson has decided to step down as of 31 January 2015. Göran Brorsson will be succeeded by Johannes Lind-Widestam, who will take office on 1 February 2015. Johannes Lind-Widestam will join Elos from Assa Oem AB, where he is president. Previously, Lind-Widestam was Purchasing Director at Nobel Biocare and responsible for Swedish operations at Kitron. Stig-Arne Blom, Chairman of the Elos Board, comments

    Elos Interim report 1 January – 30 September 2014

    · Net sales for continuing operations amounted to SEK 274.7 M (271.6), corresponding to a decline of 1.3%*. Order bookings for continuing operations totalled SEK 301.4 M (273.6), up 7.7%*. · Operating profit for continuing operations totalled SEK 24.5 M (17.8). The higher earnings resulted primarily from continued improved efficiency. · Profit after net financial items for continuing operations was SEK 22.8 M (13.2). Net financial items were positively impacted by exchange-rate differences of SEK 1.9 M (0.0). · Profit after tax for continuing operations amounted to SEK 18.8 M (10.6)

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media

    Twitter